New drug combo shows promise in early cancer trial
NCT ID NCT04344795
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This early-phase study tested a new drug called TPST-1495, alone or with pembrolizumab, in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baystate Gynecologic Oncology
Springfield, Massachusetts, 01107, United States
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
SCRI-OK Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Baltimore, Maryland, 21287, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.